You are currently viewing the abstract.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Abstract
In this issue of Science Translational Medicine, Guo et al. discuss the intriguing possibility that intracellular tumor antigen–specific monoclonal antibodies (mAbs) inhibit tumor growth and metastasis and prolong survival of tumor-bearing mice. Here, I discuss the implications of using intracellular targets in mAb-based immunotherapy as well as the possible underlying mechanisms of action.
Footnotes
Citation: S. Ferrone, Hidden Immunotherapy Targets Challenge Dogma. Sci. Transl. Med. 3, 99ps38 (2011).
- Copyright © 2011, American Association for the Advancement of Science
